Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03802604
Title Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group

triple-receptor negative breast cancer

breast adenocarcinoma


Atezolizumab + Talimogene laherparepvec

Age Groups: senior | adult
Covered Countries ESP

No variant requirements are available.